ASX Announcements
Memphasys is committed to providing shareholders with complete, up-to-the-minute information about the Company. Contact, stock, and corporate information can be found in this section of the website and on the Australian Securities Exchange.
2026 ASX Announcements
1 July 2026 – Memphasys Secures A$430K Exclusive Thailand Commercialisation Agreement for Felix™
25 June 2026 – UK Market Entry & Acceleration of Commercial Expansion
18 June 2026 – Successful $1.2M Placement and Convertible Note Extended
1 June 2026 – South East Asian Commercialisation Agreement Secured
27 May 2026 – ITL Orders 1000 Felix™ Cartridges Across Existing and New MENA Markets as Regional Demand Accelerates
19 May 2026 – New Chair Appointed
17 April 2026 – Quarterly Report – Period Ended 31 March 2026
7 April 2026 – Memphasys Investor Webinar and Release of Updated Investor Presentation
20 March 2026 – Memphasys Maintains Uninterrupted Middle East Operations
27 February 2026 – Quarterly Report – Period Ended 31 March 2026
9 February – Memphasys Secures TGA Approval for Felix System
3 February – Regulatory Submissions Lodged as Felix™ Commercial Momentum Builds Across Australia, India and the United Kingdom
2 February – Qatar’s Largest IVF Institution Places First Major Repeat MENA Orders for Felix™
22 January – December 2025 Quarterly Activities Report and Appendix 4C
2025 ASX Announcements
30 December 2025 – Memphasys Extends Convertible Note Repayment Terms
29 December 2025 – Memphasys Secures CE Mark Approval for Felix System
23 December 2025 – Memphasys Secures Long-Term European Supply Agreement
18 December 2025 – Key MENA Partner Secures Early Felix™ Cartridge Order
10 December 2025 – Memphasys Implements Leadership Restructure
8 December 2025 – Felix Middle East Direct Sales Strategy
20 November 2025 – 2025 AGM Results
November 2025 – Laser-focused on FelixTM Commercialisation – INVESTOR PRESENTATION
20 November 2025 – Chair Address to Shareholders
11 November 2025 – Section 708A Cleansing Statement
10 November 2025 – Completion of Entitlement Offer to Support Felix™ Commercialisation Activities
31 October 2025 – September 2025 Quarterly Activities Report and Appendix 4C
28 October 2025 – Memphasys Accelerates Growth with Indian Commercial Supply Agreement Under New Global Go-Direct Strategy
24 October 2025 – Memphasys Expands Felix Commercial Footprint in Japan
20 October 2025 – Response to ASX Aware Letter
20 October 2025 – Board Changes
10 October 2025 – Rights Issue Prospectus despatched
8 October 2025 – Company Secretary Appointment/Resignation
2 October 2025 – Target Market Determination
2 October 2025 – ENTITLEMENT OFFER PROSPECTUS
1 October 2025 – Cleansing Statement
30 September 2025 – Adjustment to FY25 Results
25 September 2025 – Laser-focused on Felix Commercialisation ASX | MEM – INVESTOR – PRESENTATION
22 September 2025 – Memphasys’ Placement Accelerates FelixTM Commercialisation and Manufacturing Scale-Up, Operating Costs Slashed by 40%
18 September 2025 – Trading Halt
18 September 2025 – Memphasys Secures Significant ITL Contract Upgrade to $390K and Territory Expanded to 1st EU-member State, Turkey
8 September 2025 – Memphasys Signs Exclusive Middle East Partnership, Unlocking Growth for Felix™
8 August 2025 – A high-impact, high-potential opportunity in global growth markets
30 July 2025 – June 2025 Quarterly Activity Report and Appendix 4C
25 July 2025 – Board Update
25 July 2025 – 2025 General Meeting | Change of Meeting Venue
9 July 2025 – Notice of General Meeting
30 June 2025 – Appendix 4E- Preliminary final report
30 June 2025 – Memphasys Submits CE Mark Application for Felix™
19 June 2025 – Appointment of Non-Executive Director
26 May 2025 – Change of Auditor
8 May 2025 – RoXsta™ Mega Cell High-Throughput trial
30 April 2025 – Global Clinical Validation Positions Memphasys
14 April 2025 – Binding Commitments Secured (A$1.275m)
3 April 2025 – RoXstaTM Oxidative Stress Measurement in Cattle
24 March 2025 – Felix™ Pivotal Clinical Trial Confirms Best-in-Class
13 March 2025 – R&D Tax Rebate Loan
28 February 2025 – Extension of Convertible Notes
28 February 2025 – Half Year Report
26 February 2025 – Unlocking Global Market Potential
24 February 2025 – Felix™ Clinical Trial Data Lock Completed
17 February 2025 – Brazil IVF Market Expansion
11 February 2025 – Final Patient Visit in Felix™ Trial
16 January 2025 – RoXstaTM Diagnostic Potential Publication
6 January 2025 – FelixTM Utilisation Testing in China (Heranova)